Lannett received FDA approval for its ANDA for Hydrocodone Bitartrate and Acetaminophen Tablets USP, 5 mg/325 mg, 7.5 mg/325 mg and 10 mg/325 mg, the therapeutic equivalent to the reference listed drug, Norco Tablets, of Allergan (19.95)
Arthur Bedrosian, chief executive officer of Lannett stated, "We plan to launch all of our recently approved products in our new fiscal year, which begins next week. With a number of drug applications pending at the FDA, both our own filings and those of our alliance partners, we believe additional approvals are forthcoming."